IROSUSTAT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H15NO5S
Molecular Weight	309.338
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

NS(=O)(=O)OC1=CC=C2C(OC(=O)C3=C2CCCCC3)=C1

InChI

InChIKey=DSLPMJSGSBLWRE-UHFFFAOYSA-N

InChI=1S/C14H15NO5S/c15-21(17,18)20-9-6-7-11-10-4-2-1-3-5-12(10)14(16)19-13(11)8-9/h6-8H,1-5H2,(H2,15,17,18)

HIDE SMILES / InChI

Molecular Formula	C14H15NO5S
Molecular Weight	309.338
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. It did not stimulate the growth of estrogen-sensitive MCF-7 breast cells in vitro. Irosustat was in phase II clinical trials for the treatment of breast cancer and endometrial cancer and phase I clinical trial for the treatment of prostate cancer. However, this research has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Steryl-sulfatase 33	Inhibitor 8,297		8.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Endometrial cancer 43	Primary	Phase II 1,132	Unknown
Breast cancer 434	Primary	Phase II 1,132	Unknown
Prostate cancer 178	Primary	Phase I 428	Unknown

C_max

Value	Dose	Analyte	Population
10.44 ng/mL	5 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
72.3 ng/mL	40 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
159.4 ng/mL	80 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
1.94 ng/mL	1 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
33.31 ng/mL	20 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
16323 ng × h/mL	20 mg single, oral	IROSUSTAT plasma	Homo sapiens
121 ng × h/mL	5 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
681.2 ng × h/mL	40 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
1229 ng × h/mL	80 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
26.86 ng × h/mL	1 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens
432.2 ng × h/mL	20 mg 1 times / day steady-state, oral	IROSUSTAT plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
28.5 h	20 mg single, oral		IROSUSTAT plasma	Homo sapiens

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P002XCK	https://www.1pchem.com/search?query=1P002XCK
AOBIOUS INC	AOB5998	http://aobious.com/aobious/search?search_query=AOB5998
Axon MedChem	2892	https://www.axonmedchem.com/product/2892
BOC Sciences	288628-05-7	http://www.bocsci.com/description.asp?cas=288628-05-7
Chem Scene	CS-0003463	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0003463

Showing 1 to 5 of 15 entries

Previous1 2 3Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

40 mg per day

Route of Administration: Oral

In Vitro Use Guide

The ER+ MCF-7 breast cancer cell line was used to test in vitro whether the Irosustat possessed any estrogenic properties. Irosustat over the range from 10(−11) to 10(−5) M had no significant effect on the proliferation of MCF-7 cells.